secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sana Biotechnology, Inc. (SANA)
CIK:        0001770121
Form:       8-K
Filed at:   2023-05-08T23:59:59+00:00
Accession:  0001564590-23-007072
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sana Biotechnology Q1 net loss $82.1M; advancing SC291 trial with data expected H2 2023
--------------------------------------------------------------------------------

- Cash $355.1M, supports operations into 2025; non-GAAP operating cash burn $74.8M for Q1.
- SC291 Phase 1 ARDENT trial enrolling; granted Fast Track for r/r large B-cell lymphoma and CLL.
- Plan to file INDs for SC262 and SG299 in H2 2023; SC451 IND in 2024.
- Appointed Dr. Doug Williams as President of R&D and Dr. Gary Meininger as CMO.
- Net loss $82.1M ($0.43/share) vs $31.4M ($0.17) prior year; R&D expense $67.2M down 7.6%.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1770121/000156459023007072/0001564590-23-007072-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1770121/000156459023007072/sana-8k_20230508.htm
  HTML page:      https://secwatch.observer/filing/0001564590-23-007072

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer